DNPUF (Sumitomo Pharma Co) Growth Rank: 4 (As of Aug. 08, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DNPUF Sumitomo Pharma Co Ltd DNPUF
69 GF Score
Price $8.41
GF Value $5.53
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Sumitomo Pharma Co Growth Rank?

Sumitomo Pharma Co DNPUF 69 Growth Rank is 4 as of Aug. 08, 2026, which is at its 10-year median of 4.00. GuruFocus rates DNPUF with a GF Score™ of 69/100 and a GF Value™ of $5.53 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Sumitomo Pharma Co has the Growth Rank of 4.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Sumitomo Pharma Co Growth Rank Related Terms

DNPUF vs ZTS: Growth Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sumitomo Pharma Co's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sumitomo Pharma Co Growth Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sumitomo Pharma Co's Growth Rank distribution charts can be found below:

* The bar in red indicates where Sumitomo Pharma Co's Growth Rank falls into.


DNPUF
69GF Score
Sumitomo Pharma Co Ltd DNPUF
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 4 mean?
Sumitomo Pharma Co (DNPUF) has a Growth Rank of 4 as of Aug. 08, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Sumitomo Pharma Co and its competitors. This is near median its historical median of 4.00. Over the past decade, Sumitomo Pharma Co's Growth Rank has ranged from 1.00 to 10.00.
Is Sumitomo Pharma Co's Growth Rank too high?
Sumitomo Pharma Co's current Growth Rank of 4 is near median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Sumitomo Pharma Co has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sumitomo Pharma Co's Growth Rank compare to ZTS?
Sumitomo Pharma Co's Growth Rank of 4 can be compared against companies in the Drug Manufacturers industry. Historically, Sumitomo Pharma Co's own Growth Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Drug Manufacturers company?
A good Growth Rank depends on the Drug Manufacturers industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Sumitomo Pharma Co and its competitors. Sumitomo Pharma Co's current Growth Rank is 4, which is near median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sumitomo Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Sumitomo Pharma Co (DNPUF) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.53, compared to a current price of $8.41 — trading 52% above its estimated fair value. The current Growth Rank is 4, which is near median its 10-year median of 4.00. Sumitomo Pharma Co's overall GF Score™ is 69/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Sumitomo Pharma Co (DNPUF), the current Growth Rank is 4 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sumitomo Pharma Co (DNPUF) Overvalued in 2026?

Based on GuruFocus' analysis, Sumitomo Pharma Co stock appears to be overvalued. The current stock price of $8.41 is trading 52% above its estimated GF Value™ of $5.53. GuruFocus considers Sumitomo Pharma Co to be Significantly Overvalued.

Key valuation signals for DNPUF:

  • Growth Rank: 4 (near median its 10-year median of 4.00)
  • GF Value™: $5.53 vs. price of $8.41 (52% above fair value)
  • GF Score™: 69/100 with 7 warning signs

No single metric tells the full story. See the DNPUF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sumitomo Pharma Co Business Description

Address 6-8, Doshomachi 2-chome, Chuo-ku, Osaka, JPN, 541-0045
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
69GF Score

Get the complete analysis for DNPUF

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.41
Price
$5.53
GF Value